TD Q2 Beat Confirms Base Case, But Validation Risk Keeps Rating at WAIT

What happened

TD's Q2 earnings beat expectations, with record net income and robust profitability, driven by strong Canadian banking and expense discipline. Management reiterated its FY2026 U.S. AML remediation spend of ~$500M pre-tax, the $2.9B U.S. net income target, and the $7B buyback, consistent with the DeepValue master report's base case. However, the DeepValue analysis emphasizes that the stock's next leg depends on clean internal audit validation in 2026, not quarterly beats, as the market already prices contained remediation costs. The risk of scope expansion or timeline extension beyond 2027 remains a key overhang, and the current valuation near $97 offers limited margin of safety. Thus, despite the strong quarter, the thesis remains unchanged: wait for either a lower entry or clearer validation evidence.

Implication

Investors should monitor FY2026 disclosures for any revision to AML spend above $500M or signals of audit rework, which would trigger thesis break. Accumulate only near $88 attractive entry.

Thesis delta

The strong Q2 beat does not change the fundamental calculus—the stock's risk/reward is still dominated by remediation execution, not earnings momentum. The DeepValue report's WAIT rating remains appropriate as the upside from clean validation is already discounted, while downside risks from scope creep are underappreciated. The article confirms guidance aligns with the base case, leaving no catalyst to upgrade the thesis.